菜单

Newsletter: February 2025

Company Announcements

    WuXi Biologics Achieves Major Milestones at Ireland Site with Multiple 16,000 L PPQ Success and HPRA GMP Authorizations
    WuXi Biologics Germany to Enhance Capabilities with New Prefilled Syringes Line
    WuXi Biologics Launches WuXia RidGS for Non-Antibiotic Cell Line Development

Partner Spotlight

    WuXi Biologics Announces Agreement with Candid Therapeutics on Trispecific T-Cell Engager
    WuXi Biologics and Sino Biopharm Sign Discovery Service Agreement for First-in-Class Biologics
    WuXi Biologics and Hangzhou DAC Signed Research Service Agreement with Aadi Bioscience on Three Novel ADCs

Financial Insights

    WuXi Biologics CEO Dr. Chris Chen: Poised for Accelerated Growth

Green Goals and Sustainability Achievements

    WuXi Biologics Commits to PSCI and Receives Award for Sustainable Supply Chain Leadership
    WuXi Biologics Ranks Top in 2024 Dow Jones Sustainability Indices for Second Consecutive Year
    WuXi Biologics Included in UNGC 20 Case Examples of Sustainable Development for 20 Years Collection
    WuXi Biologics Receives AAA MSCI ESG Rating for Second Consecutive Year
    WuXi Biologics Receives ESG Corporate Platinum Award from The Asset for Fourth Consecutive Year